Literature DB >> 26356240

Quality of Life in Patients With Chronic Rhinosinusitis and Sleep Dysfunction Undergoing Endoscopic Sinus Surgery: A Pilot Investigation of Comorbid Obstructive Sleep Apnea.

Jeremiah A Alt, Adam S DeConde, Jess C Mace, Toby O Steele, Richard R Orlandi, Timothy L Smith.   

Abstract

IMPORTANCE: Patients with chronic rhinosinusitis (CRS) have reduced sleep quality linked to their overall well-being and disease-specific quality of life (QOL). Other primary sleep disorders also affect QOL.
OBJECTIVE: To determine the impact of comorbid obstructive sleep apnea (OSA) on CRS disease-specific QOL and sleep dysfunction in patients with CRS following functional endoscopic sinus surgery. DESIGN, SETTING, AND PARTICIPANTS: Prospective multisite cohort study conducted between October 2011 and November 2014 at academic, tertiary referral centers with a population-based sample of 405 adults. INTERVENTION: Functional endoscopic sinus surgery for medically refractory symptoms of CRS. MAIN OUTCOMES AND MEASURES: Primary outcome measures consisted of preoperative and postoperative scores operationalized by the Rhinosinusitis Disability Index (RSDI) survey, the 22-item Sinonasal Outcome Test (SNOT-22), and the Pittsburgh Sleep Quality Index (PSQI). Obstructive sleep apnea was the primary, independent risk factor.
RESULTS: Of 405 participants, 60 (15%) had comorbid OSA. A total of 285 (70%) participants provided preoperative and postoperative survey responses, with a mean (SD) of 13.7 (5.3) months of follow-up. Significant postoperative improvement (P < .05) was reported across all mean disease-specific QOL measures for both participants with and without comorbid OSA. Participants without OSA reported significant greater improvement in unadjusted mean (SD) RSDI global scores (−25.0 [23.3] vs. −16.5 [22.1]; P = .03), RSDI physical (−10.7 [9.2] vs. −7.3 [9.1]; P = .03) and functional (−8.4 [8.7] vs. −5.1 [7.5]; P = .03) subdomain scores, and SNOT-22 rhinologic symptom domain scores (−9.1 [7.7] vs. −5.7 [6.9]; P = .008). Participants without OSA also reported greater improvements on mean (SD) PSQI global (−1.9 [4.0] vs. −0.5 [3.7]; P = .03), sleep quality (−0.4 [0.8] vs. −0.03 [0.7]; P = .02), and sleep disturbance (−0.4 [0.7] vs. −0.1 [0.7]; P = .03) scores. The majority of these associations were found to be durable after adjustment for alternate independent cofactors using stepwise linear regression modeling. CONCLUSIONS AND RELEVANCE: Patients with CRS and comorbid OSA have poor QOL with substantial disease-specific QOL improvements following surgery. Patients who present with CRS should be assessed for primary sleep disorders and, if identified, should be treated concurrently for both CRS and OSA to improve sleep dysfunction to optimize surgical outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01332136.

Entities:  

Mesh:

Year:  2015        PMID: 26356240     DOI: 10.1001/jamaoto.2015.1673

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   8.961


  17 in total

1.  Examination of high-antibiotic users in a multi-institutional cohort of chronic rhinosinusitis patients.

Authors:  Vijay R Ramakrishnan; Jess C Mace; Zachary M Soler; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2017-01-13       Impact factor: 3.858

2.  Chronic Rhinosinusitis Is an Independent Risk Factor for OSA in World Trade Center Responders.

Authors:  Jag Sunderram; Michael Weintraub; Kathleen Black; Shahnaz Alimokhtari; Akosua Twumasi; Haley Sanders; Iris Udasin; Denise Harrison; Nishay Chitkara; Rafael E de la Hoz; Shou-En Lu; David M Rapoport; Indu Ayappa
Journal:  Chest       Date:  2018-10-25       Impact factor: 9.410

Review 3.  Sleep disruption in chronic rhinosinusitis.

Authors:  Mahboobeh Mahdavinia; Robert P Schleimer; Ali Keshavarzian
Journal:  Expert Rev Anti Infect Ther       Date:  2017-02-17       Impact factor: 5.091

4.  Comparison of surgical outcomes between patients with unilateral and bilateral chronic rhinosinusitis.

Authors:  Daniel M Beswick; Jess C Mace; Naweed I Chowdhury; Jeremiah A Alt; Peter H Hwang; Adam S DeConde; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2017-09-22       Impact factor: 3.858

Review 5.  Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis.

Authors:  Zachary M Soler; Rabun Jones; Phong Le; Luke Rudmik; Jose L Mattos; Shaun A Nguyen; Rodney J Schlosser
Journal:  Laryngoscope       Date:  2017-11-22       Impact factor: 3.325

6.  Risk of obstructive sleep apnea in African American patients with chronic rhinosinusitis.

Authors:  Jessica W Hui; Jason Ong; James J Herdegen; Hajwa Kim; Christopher D Codispoti; Vahid Kalantari; Mary C Tobin; Robert P Schleimer; Pete S Batra; Phillip S LoSavio; Mahboobeh Mahdavinia
Journal:  Ann Allergy Asthma Immunol       Date:  2017-04-27       Impact factor: 6.347

7.  Appropriateness criteria predict outcomes for sinus surgery and may aid in future patient selection.

Authors:  Daniel M Beswick; Jess C Mace; Zachary M Soler; Noel F Ayoub; Luke Rudmik; Adam S DeConde; Timothy L Smith
Journal:  Laryngoscope       Date:  2018-05-14       Impact factor: 3.325

8.  Lack of impact of radiologic septal measurements upon patient symptoms and performance of septoplasty during endoscopic sinus surgery.

Authors:  N R Rowan; Z M Soler; J C Mace; M P Camilon; C Palmer; R H Jones; T L Smith; R J Schlosser
Journal:  Rhinology       Date:  2020-08-01       Impact factor: 3.681

9.  Low 22-item sinonasal outcome test scores in chronic rhinosinusitis: Why do patients seek treatment?

Authors:  Joshua M Levy; Jess C Mace; Luke Rudmik; Zachary M Soler; Timothy L Smith
Journal:  Laryngoscope       Date:  2016-07-05       Impact factor: 3.325

10.  Improvements in sleep-related symptoms after endoscopic sinus surgery in patients with chronic rhinosinusitis.

Authors:  Edward El Rassi; Jess C Mace; Toby O Steele; Jeremiah A Alt; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2015-12-17       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.